查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2068558

無法切除肝細胞癌（uHCC）：新型療法、未滿足的需求和TPP洞察報告，2026年

Unresectable Hepatocellular Carcinoma (uHCC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 53 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 英國uHCC 市場預計將從 2025 年的 4,900 萬美元成長到 2035 年的 7,100 萬美元，顯示市場穩步擴張。
  • 以下因素正在推動市場成長：
  • 擴大高成本聯合治療。
  • 透過改進診斷技術擴大合格的患者範圍
  • 儘管流行病學成長是漸進的，但高價生物製藥和較長的治療週期支撐了市場規模。
  • 歐洲完善的保險報銷機制持續促進人們獲得創新療法。
  • 未來的成長將取決於下一代免疫療法和針對抗藥性機制的新型聯合治療策略。

對無法切除肝細胞癌（uHCC）新興療法和治療策略的見解

Thelansis 發布的「無法切除肝細胞癌 (uHCC)：新型療法、未滿足的需求和 TPP 洞察報告，2026 年」對該適應症的關鍵新興療法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

無法切除肝細胞癌（uHCC）概述

無法切除性肝細胞癌（uHCC）是一種侵襲性極強的原發性肝臟惡性腫瘤，其特徵是肝內腫瘤負荷廣泛、多發、侵犯主要血管或肝儲備功能不足，使得原發性切除或肝移植幾乎不可能。此疾病幾乎無一例外地發生於慢性肝損傷和潛在肝硬化（主要由乙型或C型肝炎病毒感染、酒精性肝病或代謝功能障礙相關性脂肪肝（MASLD）引起）的背景下。從生物學角度來看，其特徵是侵襲性血管生成、顯著的免疫逃脫以及源自腫瘤的致癌性訊號通路的過度活化。臨床上，患者病情進展進行性，以進行性肝補償為特徵，常出現腹水、黃疸及嚴重門靜脈高壓，且對藥物治療無效。由於腫瘤本身對傳統細胞毒性化學療法具有抗藥性，且在晚期局部和區域治療（例如經動脈化療栓塞術）也難以實施，因此治療方案完全依賴全身性治療。目前一線治療的標準已明顯從傳統的蛋白酪氨酸激酶抑制劑單藥治療轉變為全身性聯合治療，後者已成為普遍首選。特別是，將免疫查核點抑制劑（PD-L1/PD-1抑制劑）與標靶抗血管新生治療（VEGF抑制劑）或CTLA-4抑制劑協同聯合應用，旨在積極克服高度免疫抑制的腫瘤微環境，並顯著延長患者的總存活期。

主要亮點

  • 在法國，預計新增病例數將從 2025 年的 7,874 例增加到 2035 年的 8,033 例，這表明疾病負擔略有增加。
  • 診斷率仍高達 85.0%，反映出整個醫療保健系統具有很高的偵測能力。
  • 治療率仍只有 76.2%，凸顯了確診患者與接受治療的患者之間仍然存在的差距。
  • 治療模式正朝向以免疫療法為基礎的聯合治療（IO + 抗 VEGF/CTLA-4）轉變，成為新的治療標準。
  • 儘管近年來治療取得了進展，但晚期疾病患者或對治療有抗藥性的患者仍然存在未被滿足的需求。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

  • 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更多見解，從而進一步完善了調查結果。
  • 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

  • PowerPoint簡報
  • MS Excel

主要問題

  • 詳細的競爭格局趨勢
  • 管道分析
  • 符合新興療法條件的患者
  • 大公司
  • 主要作用機制
  • 發布日期預測等。
  • 臨床試驗趨勢分析
  • 目標患者群
  • 試驗終點
  • 測試設計
  • 受試者招募標準等。
  • 未滿足的需求和機遇
  • 目前主要療法的有效性
  • 未滿足需求的關鍵領域
  • 主要未滿足需求的市場規模估算
  • 目標產品概況
  • 屬性和級別
  • 醫生開立的處方
  • 預期患者佔有率
  • 關鍵意見領袖對領先新興療法的見解
  • 意識
  • 預期用途/處理線
  • 主要未滿足需求得到滿足的程度
  • KOL評論

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • InnoBM Pharmaceuticals Co., Ltd.
  • Chengdu New Radiomedicine Technology Co. LTD.
  • BeiGene
  • Hoffmann-La Roche
  • Beijing Gene Key Life Technology Co., Ltd
  • Akeso
  • AstraZeneca
  • Tvardi Therapeutics, Incorporated
  • Genentech, Inc.
  • RayzeBio, Inc.
  • Shanghai Henlius Biotech

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要療法概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 診斷和治療過程/演算法
  • 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

  • 重點
  • 科學屬性
  • 商業性屬性
  • 產品定位

第4章：初步調查

  • 目前治療狀態
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療環境
  • 當前挑戰
  • 未滿足的需求
  • 新興療法
  • 主要治療方法與目標患者族群的比較
  • 主要特點和優勢
  • 未來治療前景
  • 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

  • 新興療法的主要未滿足需求和未來成就
  • TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

簡介目錄

Unresectable Hepatocellular Carcinoma (uHCC) Emerging Therapy and TPP Insights

Thelansis's "Unresectable Hepatocellular Carcinoma (uHCC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Unresectable Hepatocellular Carcinoma (uHCC) Overview

Unresectable hepatocellular carcinoma (uHCC) is a highly aggressive primary liver malignancy defined by an extensive intrahepatic tumor burden, multifocality, macrovascular invasion, or inadequate hepatic reserve that definitively precludes curative surgical resection or liver transplantation. Arising almost exclusively in the context of chronic hepatic injury and underlying cirrhosis-predominantly driven by hepatitis B or C viral infections, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease (MASLD)-the disease is biologically characterized by intense tumor-driven angiogenesis, profound immune evasion, and the rampant activation of oncogenic signaling pathways. Clinically, patients face a grim trajectory marked by progressive hepatic decompensation, frequently presenting with medically refractory ascites, jaundice, and severe portal hypertension. Because the tumor is inherently resistant to traditional cytotoxic chemotherapy and locoregional therapies (such as transarterial chemoembolization) become unfeasible in advanced stages, the therapeutic paradigm relies entirely on systemic interventions. The modern frontline standard of care has definitively shifted away from historical single-agent tyrosine kinase inhibitors, universally prioritizing systemic combination regimens-most notably the integration of immune checkpoint inhibitors (PD-L1/PD-1 blockade) synergistically paired with either targeted anti-angiogenic therapy (VEGF inhibition) or CTLA-4 blockade-to aggressively overcome the highly immunosuppressive tumor microenvironment and significantly extend overall survival.

Key Highlights

  • In France, incident cases are projected to increase from 7,874 in 2025 to 8,033 by 2035, indicating marginal growth in disease burden.
  • Diagnosis rate remains high at 85.0%, reflecting strong detection capabilities across healthcare systems.
  • Treatment rate stands at 76.2%, highlighting a residual gap between diagnosed and treated patients.
  • The treatment paradigm has shifted toward immunotherapy-based combinations (IO + anti-VEGF/CTLA-4) as the new standard of care.
  • Persistent unmet need exists in post-progression settings and treatment-resistant populations, despite recent therapeutic advances.

Market Overview

  • The United Kingdom uHCC market is projected to grow from $49M in 2025 to $71M by 2035, reflecting steady market expansion.
  • Market growth is driven by:
  • Increasing adoption of high-cost immunotherapy combinations
  • Expansion of eligible patient population due to improved diagnosis
  • Despite modest epidemiological growth, market value is supported by premium-priced biologics and longer treatment duration.
  • Strong reimbursement frameworks in Europe continue to facilitate access to innovative therapies.
  • Future growth will depend on next-generation immunotherapies and novel combination strategies targeting resistance mechanisms.

Insights driven by surveys with physician / key opinion leaders:

  • Survey findings are corroborated and enriched by insights from interviews with leading KOLs
  • Survey is customized based on client requirements

Deliverables format:

  • PowerPoint presentation
  • MS Excel

Key business questions answered:

  • Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
  • Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
  • Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
  • Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
  • KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • InnoBM Pharmaceuticals Co., Ltd.
  • Chengdu New Radiomedicine Technology Co. LTD.
  • BeiGene
  • Hoffmann-La Roche
  • Beijing Gene Key Life Technology Co., Ltd
  • Akeso
  • AstraZeneca
  • Tvardi Therapeutics, Incorporated
  • Genentech, Inc.
  • RayzeBio, Inc.
  • Shanghai Henlius Biotech

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

  • Key takeaways
  • Scientific attributes
  • Commercial attributes
  • Product positioning

4. Primary Market Research

  • Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
  • Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)